DBT-NII receives trademark for India's first indigenous tumour antigen SPAG9

DBT-NII receives trademark for India's first indigenous tumour antigen SPAG9 "Currently, ASPAGNIITM is being used in dendritic cell (DC) based immunotherapy in cervical, ovarian cancer and will also be used in breast cancer," the DBT said in a statement. https://ift.tt/eA8V8J